Monday, November 6, 2017

Pharmaleads CEO to Present at Bio-Europe 2017

PL265 is being developed for the treatment of neuropathic pain (oral) and ocular pain/dry eye syndrome (eye drops). PL37 is being developed for the ...

read more...

No comments:

Post a Comment